Core Viewpoint - The company announced that its self-developed Class 1 new drug, Kangyueda (Supuqi Baidong Injection), has been included in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Directory (2025) [1] Group 1: Drug Approval and Indications - Kangyueda (Supuqi Baidong) has received approval for three indications: 1. Moderate to severe atopic dermatitis in adults inadequately controlled by topical medications or unsuitable for topical treatment 2. Chronic sinusitis with nasal polyps inadequately controlled by glucocorticoid treatment and/or surgery 3. Moderate to severe seasonal allergic rhinitis in adults with symptoms inadequately controlled by nasal glucocorticoids combined with antihistamines [1]
康诺亚：康悦达纳入国家基本医疗保险药品目录